Sydnexis, Inc., a pre-commercial stage biopharmaceutical company focused on the treatment of pediatric myopia, has appointed Perry J. Sternberg as Chief Executive Officer and as a member of the Board of Directors. Sternberg is an accomplished pharma/biotech executive with more than 30 years in the industry and 15 years in eye care. Perry will provide leadership experience to help guide Sydnexis’ strategic direction and next phase of growth.

 

Perry brings commercial leadership including oversight of more than 20 product launches across a wide range of therapeutic areas and markets. His tenure in eye care spans 15 years across Novartis, Bausch & Lomb, and Shire where he was responsible for the U.S. commercial organization and managing the company’s product portfolio in five franchises. Perry led the build-out of the Ophthalmic business unit and launch of Xiidra in 2016, the first FDA-approved treatment for the signs and symptoms of dry eye disease. Perry was a key member of the leadership team responsible for the sale of Shire to Takeda in January 2019 at an aggregate value of more than $62 billion. Subsequently, the successful launch of Xiidra led to its sale by Takeda to Novartis in May 2019 in a transaction valued at greater than $5 billion.

 

“Perry’s appointment comes at a pivotal time for Sydnexis as we continue to advance our lead asset, SYD-101, to slow the progression of pediatric myopia and the risk of associated co-morbidities,” said Jeffry Weinhuff, Managing Partner at Visionary Venture Fund and Lead Board Director at Sydnexis. “Perry has deep expertise in commercialization of new therapies across diverse markets and extensive experience leading organizational growth and transformation. He will be a tremendous asset to Sydnexis.”